

# DANIEL-PAUL BEDNARIK

## Principal Executive Consultant

📞 443.864.1445

🌐 <https://www.linkedin.com/in/danielbednarik>

✉ [dbednarik@gmail.com](mailto:dbednarik@gmail.com)

📍 Highland, Maryland



## EXPERIENCE

### Chief Technology Officer

#### Black Canyon Bio, Inc.

📅 2024 📍 Phoenix, United States

- A new company employing credentialed neoantigens using a proprietary technology to develop peptide and mRNA vaccines (SNAP-VAC) and enriched, tumor-specific TILs (SNAP-TILs).

### Executive Consultant

#### The BioForge Group, LLC

📅 01/2024 📍 Gaithersburg, Maryland, United States

- LLC Principal Consultant  
- (3 months)  
Gaithersburg, Maryland, United States

### Executive Consultant

#### miRecule, Inc.

📅 05/2024 📍 704 Quince Orchard Road, Gaithersburg, MD

- Antibody and ADC (ARC) design.

### Senior Vice President, Molecular Engineering & Protein Design

#### NexImmune, Inc.

📅 02/2016 - 02/2024 📍 Gaithersburg, Maryland

- NexImmune, is an early stage biopharmaceutical company - The foundation of our unique approach focuses on modulating the role that T cells play within the immune system. Our proprietary nanotechnology platform, Artificial Immune Modulation (AIM™), employs natural biology to direct specific T cell-mediated immune responses capable of treating a variety of diseases.

### Vice President

#### Intrexon Corporation (Precigen)

📅 08/2013 - 04/2015 📍 Location

- 2 years 9 months Vice President, Molecular Engineering Unit (MEU) Operations (1 year 9 months) Germantown Maryland Promoted to Vice President in August, 2013 #Daniel Bednarik -- Oversees the operations of the company's Molecular Engineering Unit and synthetic biology programs, with emphasis on new gene switch designs and their translation to immunoncology (IO) and adoptive T-cell therapies (CAR-T). Works closely with the Health Sector Division head and Senior Management and is a member of the Executive Committee led by Randal J. Kirk (Chairman & CEO). The MEU employs Intrexon's proprietary technologies that grounds the company's commercial efforts for synthetic biology approaches to treat cancer, and other diseases. The MEU serves as a central nexus to support all corporate divisions programs. Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU

## SUMMARY

Executive Scientist and Translational Entrepreneur - Principal Consultant

## GRANT AWARDS

### DARPA CONTRACT - 2006.

Manufacturing of novel vaccines using a non-host system. \$1,700,000.

CANADIAN INSTITUTES OF HEALTH RESEARCH - 2006. \$2,000,000 for Cardiome Pharma Corporation.

American Foundation for AIDS Research - 1986. \$500,000

National Institutes of Health (NIH) R21 - 1986.

## SKILLS

AI/Bioinformatics Database Design

Translational Research

FDA/Regulatory

Genomics

Oncology

Infectious Disease

Cardiovascular Disease

Cell Line Development

Molecular Modeling & Design

## FIND ME ONLINE

### LinkedIn

[www.linkedin.com/in/danielbednarik](https://www.linkedin.com/in/danielbednarik)

### Selected Publications (PubMed)

<https://pubmed.ncbi.nlm.nih.gov/?term=Bednarik+D>

## EXPERIENCE

---

### Senior Director, Molecular Engineering Unit Operations

#### Intrexon Corporation (Precigen)

📅 08/2012 - 08/2013 📍 Germantown, Maryland

- Molecular Engineering Unit (MEU) Operations (1 year 1 month) Germantown, Maryland Oversees the company's Molecular Engineering Unit and program
- Works closely with the COO, CSO, President of the Human Therapeutics Division (HTD), Senior Director of Translational Research, Business Development, and Cell Engineering Unit (CEU)
- The MEU employs Intrexon's proprietary 'Ultravector Technology' that grounds the company's commercial efforts for gene therapy, multigenic gene program expression, and synthetic biology for treatment of cancer, and other diseases
- The MEU is a pivotal facilitator of Translational Medicine/Research for Intrexon
- Addresses molecular technology needs to foster partnerships, new business development opportunities, and ensures MEU processes are optimized to maintain seamless operation for both company and external partners
- Dr. Bednarik and his team specialize in therapeutic miRNA solutions

---

### Director, Genomics & Bioinformatics

#### Cardiome Pharma Corporation

📅 11/2007 - 09/2012 📍 Vancouver, British Columbia

- 7 years Director, Genomics & Bioinformatics; Head, Infectious Diseases Program (4 years 11 months) Vancouver, British Columbia I was acquired by Cardiome initially as a consultant to transition the Artesian assets into the company for two years, then hired by the company. I worked for Cardiome in total for 7 years. Cardiome is a research-based biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the quality of life and health of patients. We strive to find innovative medicines that provide value to patients, physicians and healthcare systems. While working for Cardiome, I have focused efforts on development of new biomarker-driven efforts to simplify clinical trial stratification. I conceived and launched the Cardiome Antiviral Discovery program - This program couples the discovery and development of viroporin proteins as a target for antiviral drug development.

---

### Vice President & Cofounder

#### Artesian Therapeutics, Inc.

📅 01/2002 - 01/2005 📍 Gaithersburg, MD

- Inc. VP & Cofounder - Cardiovascular Biology (3 years) Gaithersburg, MD Served as co-founder of company spin out from Gene Logic, Inc. in 2002. Quickly defined relationships between dysregulation of gene expression and small molecule SAR. The program led to two therapeutic classes of molecules designed to restore ejection of blood to the failing heart while suppressing beta-agonist pathways. This led to a rapid exit via sale of the company to Cardiome Pharma Corp. in October, 2005.

## EXPERIENCE

---

### Director, Cardiovascular Database Development

#### Gene Logic, Inc.

📅 1997 - 2002 📍 Gaithersburg, MD

- Dr. Bednarik created the largest known cardiovascular gene expression database for Gene Logic, which served as a prized source of cardiovascular disease data for multiple pharma companies, and grounded the basis for founding Artesian Therapeutics. This database integrated unique personal and clinical biosample attributes with changes in gene expression in disease-vs-normal cardiovascular tissues derived from man and animal model systems. Along with other disease programs at Gene Logic, it propelled a revolution in disease pathway and drug discovery.

---

### Executive Consultant, Operations

#### Microbion Corporation

📅 07/2015 - 06/2017 📍 Vancouver, Canada; Bozeman, MT

- Vancouver, Canada and Bozeman MT Microbion's bismuth-thiol (BT) family of compounds have potent, broad spectrum efficacy against all antibiotic resistant bacteria tested to date. Additionally they have the highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens.

---

### Consultant

#### Acidophil LLC

📅 03/2017 - 02/2024 📍 Baltimore, MD

Part of Red Abbey Ventures and managed by Dr. Philip Goelet, Acidophil manages several new portfolio companies focused in agriculture, veterinary, technology development.

---

### Consultant

#### Antidote Therapeutics, Inc.

📅 08/2016 - 02/2017 📍 Gaithersburg, MD

- Consultant (7 months) Gaithersburg, MD Development of stable cell lines for company's RCB and MCB
- Expression of nicotine monoclonal antibodies that facilitate smoking cessation

---

### Consultant

#### BioIT Solutions, Inc.

📅 03/2012 - 06/2017 📍 Silver Spring, MD

- (5 years 4 months) Silver Spring, Maryland BioIT is a Silver Spring Maryland-based software company specializing in Biotechnology applications, providing a novel line of Portal Products
- The founders of BioIT originated from Human Genome Sciences, Inc. (HGS) where the CIO, Michael Fannon, served as the primary architect and designer of that company's cutting edge bioinformatic database and genomics tools
- My role with BioIT is to help extend product development and bring this unique capability to clients in the biotechnology and pharmaceutical industry on a customized basis
- My experience with bioinformatics and genomics provides BioIT with new potential user bases and development of new functionality

## EXPERIENCE

---

### Director, Advisory Board

#### Ablitech, Inc.

📅 01/2012 - 12/2012 📍 Baltimore, MD

- Inc. Director, Advisory Board - The company's lead siRNA and antisense DNA delivery product, Versadel, was undergoing pre-clinical testing with the intention of partnering with major pharma.
  - My role for Ablitech is to establish and organize the Scientific Advisory Board (SAB) and assist in the critique of ongoing scientific projects.
- 

### Director, Business Development

#### ExonHit Therapeutics, Inc.

📅 10/2009 - 09/2010 📍 Gaithersburg, Maryland

- Gaithersburg, Maryland Directed new business development efforts, partnering, and translation of corporate technology to practice in the business sector.
  - Worked directly with Vice President, Business Development and Vice President of R&D to execute database partnering opportunities.
- 

### Consultant & Advisor

#### Indel Therapeutics, Inc.

📅 03/2009 - 01/2012 📍 Vancouver, British Columbia

- (3 years) Vancouver, British Columbia Indel Therapeutics Inc. is a biopharmaceutical company dedicated to developing new drugs to address the global health crisis caused by antibiotic resistance
  - The Company has a growing pipeline of novel antibiotic drug discovery programs that focus on curing difficult-to-treat and hospital-acquired infections.
  - These programs are based on Indel's paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.
  - My role for Indel Therapeutics has been to identify new opportunities, assist in the company's interface with the US Dept. of Defense, and provide insights and advice regarding bioinformatics, database development, and recruitment of funding.
- 

### Consultant

#### NX Pharmagen, Inc.

📅 01/2009 - 01/2012 📍 Miami, FL

Focused on the development of exosome technology for diagnostic applications directed at glioblastoma (GBM).

- NX Pharmagen, Inc. (3 years)
- 

### Consultant

#### Bradmer Pharmaceuticals, Inc.

📅 10/2008 - 01/2009 📍 Miami, FL

Focused on development of therapeutics for glioblastoma (GBM) - Technologies transferred to NX Pharmagen, Inc.

- Inc. Consultant (4 months) Consulting for drug development
- 

### Consultant

#### Cardiome Pharma Corporation

📅 10/2005 - 11/2007 📍 Vancouver, BC

- (2 years 2 months) Post-acquisition of Artesian Therapeutics - Responsibilities included transition of CRPM and BRPM programs into Cardiome Pharma Corp., acting as Program Manager and designing new animal studies for therapeutic compound validation

## EXPERIENCE

---

### Director

#### Advanced Bioresearch Associates

📅 08/1997 - 09/1998 📍 Rockville, MD

- Scientific Affairs - (1 year 2 months) Preclinical study development and reporting for the medical device and pharmaceutical industry

---

### Senior Scientist

#### Human Genome Sciences, Inc. (HGS)

📅 1993 - 1997 📍 Rockville, MD

- Served as molecular biologist and bioinformatics scientist - Discovery, characterization, and patenting of novel genes for development of novel therapeutic proteins.

---

### Chief, Molecular Genetics Section

#### Centers for Disease Control and Prevention

📅 1989 - 1993 📍 Atlanta, GA

- Identification of novel retrovirus sequences in human and animal biosamples.
- Studies of HIV latency.

---

### Assistant Professor

#### Winship Cancer Center, Dept. of Pathology, Emory University

📅 1991 - 1993 📍 Atlanta, GA

- Studies focused on virus-mediated cardiomyopathy; laboratory of Dr. Aftab Ansari.
- Transcriptional control mechanisms for HIV and SIV; laboratory of Dr. Aftab Ansari.

## EDUCATION

---

### Instructor/Junior Faculty, The John's Hopkins Oncology Center

#### The John's Hopkins University Oncology Center

📅 1985 - 1989 📍 Baltimore, MD

---

### Post-Doctoral Fellow, Oncology and Cancer Biology/Virology

#### The Johns Hopkins University Oncology Center

📅 01/1985 - 01/1989 📍 Baltimore, MD

---

### MSc, PhD, Biochemistry

#### Temple University School of Medicine

📅 01/1980 - 01/1985 📍 Philadelphia, PA

---

### BA, Biology

#### Rider University

📅 01/1976 - 01/1980 📍 Lawrenceville, NJ

---

### High School Diploma

#### Somerville High School

📅 01/1972 - 01/1976 📍 Somerville, NJ